Drug Trial Radar · NCT06621615
Clinical Study of CVL006 Injection in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 20, 2024
Primary completion
May 20, 2028
Study completion Nov 20, 2028
Sponsor
- Lead sponsor
- Convalife (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; Observe the dose limiting toxicity (DLT) of CVL006 monotherapy in patients with advanced solid tumors, evaluate the maximum tolerated dose (MTD), and recommend the dosage for phase II clinical trials (RP2D).
Conditions
- Advanced Solid Tumor
Interventions
CVL006 InjectionBiological
CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT of CVL006 monotherapy in advanced solid tumor patients.Time frame: In Phase Ia trials, if there is a delay in the second administration 28 days after the first dose, the DLT observation period will be extended to 14 days after the second administration.
- MTD of CVL006 monotherapy in patients with advanced solid tumors.Time frame: Phase Ia trial, from the first subject to the end of the DLT observation period for the last subject.
- RP2D of CVL006 monotherapy in patients with advanced solid tumorsTime frame: From the first subject enrolled in Phase 1a to the last subject removed from Phase Ib.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.